- Home
- EWTX vs USPH Comparison
EWTX vs USPH Comparison
Compare EWTX & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- USPH
- Stock Information
- Founded
- EWTX 2017
- USPH 1990
- Country
- EWTX United States
- USPH United States
- Employees
- EWTX N/A
- USPH N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- USPH Medical/Nursing Services
- Sector
- EWTX Health Care
- USPH Health Care
- Exchange
- EWTX Nasdaq
- USPH Nasdaq
- Market Cap
- EWTX 1.6B
- USPH 1.4B
- IPO Year
- EWTX 2021
- USPH 1992
- Fundamental
- Price
- EWTX $15.40
- USPH $89.13
- Analyst Decision
- EWTX Buy
- USPH Strong Buy
- Analyst Count
- EWTX 10
- USPH 5
- Target Price
- EWTX $37.90
- USPH $110.20
- AVG Volume (30 Days)
- EWTX 875.0K
- USPH 166.3K
- Earning Date
- EWTX 11-06-2025
- USPH 11-06-2025
- Dividend Yield
- EWTX N/A
- USPH 2.02%
- EPS Growth
- EWTX N/A
- USPH 116.39
- EPS
- EWTX N/A
- USPH 2.29
- Revenue
- EWTX N/A
- USPH $722,201,000.00
- Revenue This Year
- EWTX N/A
- USPH $18.73
- Revenue Next Year
- EWTX N/A
- USPH $6.13
- P/E Ratio
- EWTX N/A
- USPH $38.98
- Revenue Growth
- EWTX N/A
- USPH 16.25
- 52 Week Low
- EWTX $10.60
- USPH $62.77
- 52 Week High
- EWTX $38.12
- USPH $101.20
- Technical
- Relative Strength Index (RSI)
- EWTX 51.61
- USPH 57.37
- Support Level
- EWTX $14.88
- USPH $86.10
- Resistance Level
- EWTX $16.08
- USPH $92.63
- Average True Range (ATR)
- EWTX 0.85
- USPH 3.32
- MACD
- EWTX -0.04
- USPH -0.07
- Stochastic Oscillator
- EWTX 50.88
- USPH 61.92
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.